Chagas Disease Treatment Market

Chagas disease is a tropical parasitic disease and is endemic in 21 countries in Latin America. Chagas disease can transmitted through blood transfusion, organ transplantation, as well as congenital and oral transmissions. Chagas disease is endemic to Latin America, however, in the recent past, there is a rise in global incidence of Chagas disease due to the migration of Latin American people to other countries. According to data published by World Health Organization (WHO), in February 2018, globally, around 6 Mn to 7 Mn people were infected with Trypansosoma cruzi, the parasite which causes Chagas disease. Benznidazole and Nifurtimox are only two drugs available for the treatment of Chagas disease. Market Dynamics Rising migration of people from endemic countries to developed economies such as the U.S. and in countries in Europe is expected to drive growth of Chagas disease treatment market. For instance, according to the data published by Public Library of Science (PLOS), in 2012, there are around 1,62,095 Bolivian adults living in Spain, in which about 97,215 are women (60%) and 64,880 are men. It was estimated that out of total immigrants from Bolivia to Spain 34,202 were found to be potentially infected with Chagas disease. Furthermore, increasing R&D activities for the development of novel treatment methods for Chagas disease is also expected to create a lucrative environment for the market growth. For instance, in 2016, researchers from Saint Louis University Center for Vaccine Development were working on developing a vaccine for Chagas disease. Scientists found Th17 cells, a special type of white blood cell that recognizes the presence of a foreign invader and helps other cells in the immune system to attack and protects the body against Trypanosoma cruzi parasite. Key features of the study • This report provides in-depth analysis of Chagas disease treatment market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, regional outlook, and competitive strategy adopted by leading players • It profiles leading players in the global Chagas disease treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans • Key companies covered as a part of this study include Nortec Quimica SA, Bayer AG, Laboratorio Elea Phoenix SA, Maprimed S.A., and Laboratório Farmacêutico de Pernambuco S/A. • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics • The global Chagas disease treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the Chagas disease treatment market Market Segmentation • By Product Type (Revenue, USD Mn, 2021-2033) o Benznidazole o Nifurtimox • By Distribution Channel (Revenue, USD Mn, 2021-2033) o Hospitals o Retail Pharmacies o Online Pharmacies • By Region (Revenue, USD Mn, 2021-2033) o North America  U.S.  Canada o Latin America  Brazil  Mexico  Argentina  Rest of Latin America o Europe  Germany  U.K.  France  Italy  Spain  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC  Israel  Rest of Middle East o Africa  South Africa  Central Africa  North Africa • Key Players o Nortec Quimica SA o Bayer AG o Laboratorio Elea Phoenix SA o Maprimed S.A. o Laboratório Farmacêutico de Pernambuco S/A